Exciting news in the field of cancer therapeutics as Granza Bio, a cutting-edge company from Y Combinator's Winter 2024 cohort, has successfully raised $7,140,000 in funding. Granza Bio is revolutionizing the fight against cancer by developing innovative therapeutics known as "attack particles" that mimic the body's immune system to target cancer cells specifically, without causing harmful side effects or toxicity to healthy cells. This recent funding will be crucial in advancing Granza Bio's research and development efforts, paving the way for groundbreaking treatments that could potentially transform the landscape of cancer therapy. Keep an eye on Granza Bio as they continue to make strides in the fight against cancer with their groundbreaking approach. For more information or to collaborate with Granza Bio, reach out to the founders at founders@granzabio.com.
.png&w=3840&q=75)
Granza Bio Secures $7.14M in Seed Funding to Advance Immune-System-Inspired Cancer Therapeutics
Recently funded 路 $7.1M SeedTechnology/Internet Services
Get the full Granza Bio (YC W24) company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Aisot Technologies
Aisot Technologies is a Zurich-based AI company pioneering advanced, AI-driven investment solutions. Spun out of ETH Zurich in 2021, aisot leverages machine learning, large language models (LLMs), and quantitative methods to deliver precise, real-time investment insights. Its AI Insights Platform empowers asset managers, funds, family offices, and treasuries to anticipate market trends, optimize strategies, and mitigate risk. Recognized across Europe and the U.S., aisot partners with leading financial institutions to redefine quantitative investment management.
$2.5M Seed
today
Dognosis
Dognosis is a deep-tech startup in Bangalore decoding canine cognition to reveal the hidden world of scent. Our vision is a world where we have cracked the olfactory code of disease, making detecting disease as easy as breathing. Our mission is to save lives by detecting disease early and advance humanity towards truly proactive and preventative medicine. Our work revolves around increasing the bandwidth of human-canine collaboration, allowing us to catch the scent of disease at scale. Our first goal is to solve for early cancer detection by pioneering a multi-cancer breath-based test - BreathEasy - that will be ultra-affordable, highly accurate, and super accessible. We're always on the lookout for passionate and ambitious people to work with us. Feel free to say hi to woof@dognosis.tech
Other recent Seed rounds
Companies that recently closed a Seed round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | Aisot Technologies Switzerland | Seed | $2.5M | today |
| 2 |  DIMENSION United States | Seed | $1.6M | today |
